The Ouut
Sign in Subscribe
Funding• North America

Toronto's ODAIA Raises $15 Million Series C for Pharma Sales Analytics

ODAIA, a Toronto company that sells AI analytics to drug makers' sales and marketing teams, has raised a $15 million Series C led by Monograph Capital

Toronto's ODAIA Raises $15 Million Series C for Pharma Sales Analytics
ODAIA

The round is smaller than the company's 2023 Series B, and ODAIA did not disclose a valuation or revenue.

ODAIA, a Toronto company that sells AI analytics to drug makers' sales and marketing teams, has raised a $15 million Series C led by Monograph Capital, the company announced.

PHM, a U.S. health media agency part of Publicis Groupe, joined as a strategic investor and signed a commercial agreement making it ODAIA's exclusive U.S. agency partner, the release said.

The round is smaller than ODAIA's last one. The company raised a $25 million Series B in 2023, co-led by Threshold Ventures and Monograph, BetaKit reported at the time. ODAIA did not say how much it has raised in total or give a valuation.

What it sells

ODAIA's software forecasts patient needs, flags missed prescription opportunities and ranks which physicians a drug brand should reach and through which channels, the company said. Its products include Field Intelligence, Marketing Intelligence and Brand Strategy Studio.

The company said four of the top 15 global pharmaceutical companies use ODAIA. It did not name them or disclose revenue.

"Pharma has proven that AI works in commercial," said Philip Poulidis, ODAIA's co-founder and CEO.

Investors

Returning investors BDC Capital, Flint Capital, Innospark Ventures, Graphite Ventures, Threshold Ventures, and Wittington Ventures also participated, according to the release.

Monograph is not a new backer. It co-led the 2023 round, and its co-founder and partner Charles Conn joined ODAIA's board then, BetaKit reported. In the Series C release, Conn praised ODAIA's "track record of helping large and specialty pharma brands reach the physicians."

ODAIA plans to use the money to expand work with its existing pharmaceutical customers and keep developing its platform, the company said.

Background

Poulidis co-founded ODAIA with Periklis Andritsos, Helen Kontozopoulos and Gael Bernard, according to BetaKit. Before the Series B, the company raised a 17.5 million Canadian dollar Series A.

Sponsored

Northline Cloud for Founders. Run your AI product on dedicated GPU capacity, with an architecture review in your first month.

Learn more
0:00